Collegium

COLL · NASDAQ🇺🇸

Overview

Earnings Dividends Seasonality Metrics

Reported earnings 7 days ago

Jornay PM Prescriber Growth

Previous year: $98.3M

+30.6%

Cash and Equivalents

$231M

Previous year: $70.6M

+227.7%

Total Assets

$1.66B

Previous year: $1.66B

-0.4%

Loading...

Collegium

Unlock previous datapoints

Upgrade

Collegium

Unlock previous datapoints

Upgrade

Collegium Revenue by Segment

Revenue by Segment

Jornay PM Revenue

CapyFin.com

Pain Portfolio Revenue

CapyFin.com

Belbuca Revenue

CapyFin.com

Xtampza ER Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Nucynta Franchise Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$1.27B

P/E Ratio

7.19

Sector

N/A

Industry

N/A

52-Week High

$49.7

52-Week Low

$24.6

Jornay PM Rx Growth

16%

Jornay PM Prescriber Growth

21%

Adjusted EBITDA

$127M

Share Repurchases

$25M

Products

Get in Touch

Resources

Collegium

Collegium

Collegium

Collegium Revenue by Segment

Revenue by Segment

Jornay PM Revenue

Pain Portfolio Revenue

Belbuca Revenue

Xtampza ER Revenue

Nucynta Franchise Revenue

Revenue & Expenses

Historical Earnings Impact

Avg. Return Before/After Earnings

Key Statistics